Recombinant human interferon alpha D in HSV-1 recurrence in the rabbit.
Recombinant human interferon alpha subtype D (RIFN alpha D) was effective in reducing the shedding of herpes simplex virus type-1 (HSV-1) induced by 6-hydroxydopamine iontophoresis followed by topical epinephrine application in previously infected rabbit corneas. A treatment schedule of RIFN alpha D, two drops QID was superior to one drop BID. RIFN alpha A also appeared to be effective in reducing viral shedding. Rabbits treated with RIFN alpha D during two episodes of adrenergically induced HSV-1 shedding, but not during anticipated episodes of spontaneous shedding, did not show a significant reduction in shedding of virus. Interferon was present in significantly higher concentration in tear samples following treatment with RIFN alpha D as compared with RIFN alpha A.
D000818:Animals; D004274:DNA, Recombinant; D004334:Drug Administration Schedule; D004837:Epinephrine / Q000627:therapeutic use; D006892:Hydroxydopamines / Q000494:pharmacology; D007370:Interferon Type I / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007478:Iontophoresis; D007635:Keratitis, Dendritic / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D009883:Ophthalmic Solutions; D016627:Oxidopamine; D011817:Rabbits; D012008:Recurrence; D012965:Sodium Chloride / Q000627:therapeutic use; D013666:Tears / Q000378:metabolism
D004274:DNA, Recombinant; D006892:Hydroxydopamines; D007370:Interferon Type I; D009883:Ophthalmic Solutions; D012965:Sodium Chloride; D016627:Oxidopamine; D004837:Epinephrine